Obinutuzumab in hematologic malignancies: Lessons learned to date - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Cancer Treatment Reviews Année : 2015

Obinutuzumab in hematologic malignancies: Lessons learned to date


The routine use of anti-CD20 monoclonal antibodies (mAbs) has improved patient outcomes in CD20-positive non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Despite the clinical success achieved with rituximab, relapses are still common with further improvements in anti-CD20 mAb efficacy required. Many novel anti-CD20 antibodies are in development, but obinutuzumab is currently the only type II glycoengineered anti-CD20 mAb in clinical testing. Obinutuzumab has increased antibody-dependent cell-mediated cytotoxicity, reduced complement-dependent cytotoxicity and enhanced direct non-apoptotic cell death. In preclinical models, obinutuzumab induced superior tumor remission compared with rituximab at the equivalent dose levels, and was active in rituximab-refractory tumors. Obinutuzumab exhibits encouraging efficacy as monotherapy in NHL, and combined with chemotherapy in relapsed/refractory NHL and treatment-naïve symptomatic CLL. In a recent randomized, phase III trial in patients with untreated comorbid CLL, overall response rate was significantly greater (78% vs. 65%, P<0.0001) and median progression-free survival was significantly prolonged (26.7 vs. 15.2months, P<0.0001) for obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil. Obinutuzumab is a type II anti-CD20 antibody that utilizes distinct mechanisms of action relative to type I antibodies like rituximab and has led to significant clinical improvement over rituximab in a phase III trial in CLL. Further trials are ongoing to determine whether such improvements in outcome will be seen in CD20-positive B-cell malignancies.



Dates et versions

hal-01962569 , version 1 (20-12-2018)



Tim Illidge, Christian Klein, Laurie Sehn, Andrew Davies, Gilles Salles, et al.. Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treatment Reviews, 2015, 41 (9), pp.784-792. ⟨10.1016/j.ctrv.2015.07.003⟩. ⟨hal-01962569⟩
23 Consultations
0 Téléchargements



Gmail Facebook X LinkedIn More